Zephyr Endobronchial Valves Improve FEV1 and Quality of Life in Heterogenous Emphysema

Abstract

reach peak benefit by week 12. However, subgroup analysis shows that this drug is primarily effective in patients with increased baseline eosinophil count or increased fraction of exhaled nitric oxide, and performs no differently than matched volume placebo in patients who do not have these proxies of type-2 inflammation; therefore, thoughtful consideration of patient candidacy is still necessary when using dupilumab as a treatment adjunct. Dupilumab is a welcome addition to a growing armamentarium against asthma mediated by type-2 inflammation, with a novel mechanism that targets both IL-4 and IL-13.